{"name":"Myomo","slug":"myomo","ticker":"MYO","exchange":"NYSE American","domain":"myomo.com","description":"Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; MyoPro2+, which comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device; MyoGames, a virtual training platform; and MyoPro 2x Video Library. In addition, the company offers MyoCare, a post-delivery program that provides follow-up care with clients, therapists, and referral sources; MYOMO; MyoPal; and MyoCoach. Its products are designed to help adults and adolescents with neuromuscul","hq":"Cambridge, MA","founded":0,"employees":"194","ceo":"Paul Gudonis","sector":"Medical Devices / Robotics","stockPrice":0.85,"stockChange":0.04,"stockChangePercent":4.94,"marketCap":"$33M","metrics":{"revenue":1000000000,"revenueGrowth":2.9,"grossMargin":66,"rdSpend":6943838,"netIncome":-15573884,"cash":15696404,"dividendYield":0,"peRatio":-3.4,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Myomo Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Myomo reported revenue of $13.4 million for the fourth quarter of 2023, a 14% increase from the same period in 2022. The company also reported a net loss of $4.1 million for the quarter.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Myomo Announces Partnership with Medtronic to Develop Wearable Robot for Stroke Patients","summary":"Myomo has partnered with Medtronic to develop a wearable robot for stroke patients. The partnership aims to improve mobility and independence for patients with stroke-related muscle weakness.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxOTVNRTy1MY2pRTjdDMkd4dFNIM0g0aTh6TzFuUEJtWmlfWVgwMmk2ZUVnczh2QUM3V2lmMEZ4a1ItSGhldlk4dVVTNGJuUnhCQXFmbUhFdjNNejFhU19WUlhoVUxhY3c0NTVFRDdrcEZWc2xINFh0QUxBbGpQZzJwcUtzOVNRTWVXd1J2WEhRcnFlUXNvcXNOT1JpSlFZZnV6UXZrczlQdEVyYWFTdk5QNzU2WFBlS2R5X1NCVWNoTjVqTFBneDY0X0VOaFNWTlJrRko5Ng?oc=5","date":"2026-03-09","type":"pipeline","source":"Business Wire","summary":"Myomo and Elevance Health Agree to Contract for Multi-State Network Participation - Business Wire","headline":"Myomo and Elevance Health Agree to Contract for Multi-State Network Participation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQTTRJRXdObHo1TS1lMTcyeXBoWUhreDRYNHdrZ0FvUGdQUmduOUpmdEFaVVowYW96Skt2a2tySDJIdjlwbVV1ZkxMT2daVWVXSGhzS3Ztc0ZKeFZfSFEyQ25Ta2UxSmV2ZFdFX1RkLUp1RHFvM05BY01qQ1VYb2VxdU1CQzZPcks1YmlORHVVZGFzZXNrLWtsaUtLclBfd29lV3JfdWZSWUE2MzBVaDhOTFZfTUM?oc=5","date":"2026-03-09","type":"pipeline","source":"Investing.com","summary":"Myomo enters network agreement with Elevance Health plans - Investing.com","headline":"Myomo enters network agreement with Elevance Health plans","sentiment":"neutral"},{"date":"2026-03-09","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-10","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOdzNqdzZ1REIzbHJWb1h2OTlKQmJudXNGSFk2VHlEY1daRmZfRXR2NkpMSzdLYjJHeENxVFlhOTFPbG1TVGFFOTZ1TDRURGNrNjlqQ2ZRdnpyUkdwZ1ZVZU1LeVJmZ3VDOEg4aU5lV09MVUFmVEpIWFpYeVZySkhqSUlDcWtyOC1yY0J3a21DQ2hNNWEwS2dZaU9oenFBcDJqSUt0T0tPMEpmNWN5aGhBV2JmWGFfeEtWTUpXYVlkMERFQQ?oc=5","date":"2025-09-11","type":"pipeline","source":"TIKR.com","summary":"5 High-Risk, High-Reward Microcap Stocks With Massive Upside Potential and Limited Analyst Coverage - TIKR.com","headline":"5 High-Risk, High-Reward Microcap Stocks With Massive Upside Potential and Limited Analyst Coverage","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQY1MzbTBzZzdqNWtMcG9pbmVyTWYyWnprdWRfZ3BpLXhvM2x2eC12cVAtQVJxWGdHZk14d2pJQmRic0JCTTQtcWVlX2l0bUxUT1hNS1RsTnpOX2YxRTNwUTRiUHQybldrcVJkY1drYVpZQTdIMlNEdGtRTjFBTW9MZ2hHTndWMXF5cG9wSWQyT0FxdzRhVUtTSC01ZWVoc2ZtVXRIY2pXYlVCZXdKQy1Ba3VDTG8yOXhlbnBmYzE2U2FldjVx?oc=5","date":"2025-04-30","type":"pipeline","source":"Medical Economics","summary":"Myomo launches MyoPro 2x, enhancing independence for patients with arm and hand paralysis - Medical Economics","headline":"Myomo launches MyoPro 2x, enhancing independence for patients with arm and hand paralysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOZi1LV2pmQVQzdFo1b1JFSVFsSWY1UjJybXVRaTYweGZfNzZoYXYzUmd5endHaTdRejlvOGtrZ0pkN1BzdUVndnE2LV80V1RnYXpVNEhlVVZlYWZlT29OM0I2Zm5yaUVRajZ2cmZsbzJFb0s0NnJ5NFlSS19pOG56VHBEZUNmc25SZkpTOU41NkZDWEZBWk92ZnVfTVFUUXVYbVNsOGR1NFFtSmstcHQyUElPTHM?oc=5","date":"2025-04-09","type":"pipeline","source":"Seeking Alpha","summary":"Myomo: Balancing CMS Tailwinds With Long-Term Risks (NYSE:MYO) - Seeking Alpha","headline":"Myomo: Balancing CMS Tailwinds With Long-Term Risks (NYSE:MYO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPczhnNXg2M0FqMTN5b2tXSUQ2TkdjLTljQlBJd3Jodmdpb1dlbnVUZmlpaWl1U2ZtXzgyX3BBYWNYd0JRcU5Jem1PUDJXSVNRd3I3bE1BZ1FoUTFtOUNwSjJXR181VExxTEk1ZjFSaGIzT2U3ZmFybC1lZFNiSVJtWl9QUDZxVjg5VFJKd05iQkE2OU13ZWVJME1YRXdOZWhLTjVXT2JwUlJwVTcwaHVr?oc=5","date":"2025-01-24","type":"pipeline","source":"Seeking Alpha","summary":"Revisiting Myomo: Valuation Reflects High Growth, But Execution Matters (NYSE:MYO) - Seeking Alpha","headline":"Revisiting Myomo: Valuation Reflects High Growth, But Execution Matters (NYSE:MYO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQdjZxX2xkcE9EdTNvaFh3NTlfZkRRNFhaQXBYSWlibTZibExUdnYzWGpLYVAwTTdNV1h0b1lKd01ocHRqRWdrODN4TnNNZlZBUTJocFRKWnBhcloxVDNoQmlmSTNFSmlkQk43bk9pSDhHZU5qZDg0ZU5HeVNTNWNtd0NoY1pkbXRYMVpYNlU5SGM3WEhBang0V2k2eVhrNzdCQVJMZWNRazgwMTd3cnc?oc=5","date":"2024-03-13","type":"deal","source":"Seeking Alpha","summary":"Myomo's Revolutionary MyoPro Brace: A Buy In Neurological Mobility Aid (NYSE:MYO) - Seeking Alpha","headline":"Myomo's Revolutionary MyoPro Brace: A Buy In Neurological Mobility Aid (NYSE:MYO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNWU5WNWVCRG1DRjFYWGZRZWFYaXppZFVBZnJtTEVnb1M2RG9WM29OV0laR2Rac2FjRmItYVBwWG5MczFKam84RGNZZXJlbVlEZnNJVThjd1M5NFB3amdBQkMyZGtzbUdJUlYxVmc3UnJobTV1R1d2dnFKNm9mSk1lRTROb1dNY1dPdnRmWW8wLWtYTE9u?oc=5","date":"2024-01-02","type":"pipeline","source":"The Business Journals","summary":"The definitive Boston biotech layoff tracker for 2023 - The Business Journals","headline":"The definitive Boston biotech layoff tracker for 2023","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["Hocoma","ReWalk","Bioness"],"therapeuticFocus":["Muscle weakness","Paralysis","Stroke rehabilitation"],"financials":{"source":"sec_edgar+yahoo","revenue":1000000000,"revenuePeriod":"2022-08-16","revenueHistory":[{"value":1000000000,"period":"2022-08-16"},{"value":2444104,"period":"2018-12-31"},{"value":1558866,"period":"2017-12-31"},{"value":1558866,"period":"2017-12-31"},{"value":1103277,"period":"2016-12-31"}],"grossProfit":26888324,"grossProfitHistory":[{"period":"2025-12-31","value":26888324},{"period":"2024-12-31","value":23185343},{"period":"2023-12-31","value":13182383},{"period":"2022-12-31","value":10253096}],"rdSpend":6943838,"rdSpendHistory":[{"period":"2025-12-31","value":6943838},{"period":"2024-12-31","value":4772013},{"period":"2023-12-31","value":2636487},{"period":"2022-12-31","value":2482489}],"sgaSpend":34346333,"operatingIncome":-14401847,"operatingIncomeHistory":[{"period":"2025-12-31","value":-14401847},{"period":"2024-12-31","value":-6206698},{"period":"2023-12-31","value":-8231549},{"period":"2022-12-31","value":-10672204}],"netIncome":-15573884,"netIncomeHistory":[{"period":"2025-12-31","value":-15573884},{"period":"2024-12-31","value":-6183729},{"period":"2023-12-31","value":-8147565},{"period":"2022-12-31","value":-10721022}],"eps":-0.37,"epsHistory":[{"period":"2025-12-31","value":-0.37},{"period":"2024-12-31","value":-0.16},{"period":"2023-12-31","value":-0.28},{"period":"2022-12-31","value":-1.52}],"cash":14132027,"cashHistory":[{"period":"2025-12-31","value":14132027},{"period":"2024-12-31","value":24372373},{"period":"2023-12-31","value":6871306},{"period":"2022-12-31","value":5345967}],"totalAssets":38636573,"totalLiabilities":27233106,"totalDebt":19382439,"equity":11403467,"operatingCashflow":-14511454,"operatingCashflowHistory":[{"period":"2025-12-31","value":-14511454},{"period":"2024-12-31","value":-3289904},{"period":"2023-12-31","value":-6172764},{"period":"2022-12-31","value":-10233542}],"capex":-3333111,"capexHistory":[{"period":"2025-12-31","value":-3333111},{"period":"2024-12-31","value":-1360125},{"period":"2023-12-31","value":-145816},{"period":"2022-12-31","value":-111793}],"freeCashflow":-17844565,"dividendsPaid":null,"buybacks":null,"employees":194,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":8933209,"ebit":-2990431,"ebitda":-2321233,"period":"2025-12-31","revenue":11353296,"epsBasic":-0.09,"netIncome":-3813938,"rdExpense":1624823,"epsDiluted":-0.09,"grossProfit":7784274,"operatingIncome":-2773758},{"sga":8432102,"ebit":-3517514,"ebitda":-3082884,"period":"2025-09-30","revenue":10090699,"epsBasic":-0.09,"netIncome":-3662915,"rdExpense":1527660,"epsDiluted":-0.09,"grossProfit":6442248,"operatingIncome":-3517514},{"sga":8641162,"ebit":-4590320,"ebitda":-4161873,"period":"2025-06-30","revenue":9652234,"epsBasic":-0.11,"netIncome":-4631972,"rdExpense":2001331,"epsDiluted":-0.11,"grossProfit":6052173,"operatingIncome":-4590320},{"sga":8339860,"ebit":-3520254,"ebitda":-3072861,"period":"2025-03-31","revenue":9831814,"epsBasic":-0.08,"netIncome":-3465058,"rdExpense":1790024,"epsDiluted":-0.08,"grossProfit":6609630,"operatingIncome":-3520254},{"sga":7300843,"ebit":-245314,"ebitda":220719,"period":"2024-12-31","revenue":12068457,"epsBasic":-0.01,"netIncome":-260081,"rdExpense":1559704,"epsDiluted":-0.01,"grossProfit":8615233,"operatingIncome":-245314},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0.85,"previousClose":0.81,"fiftyTwoWeekHigh":3.69,"fiftyTwoWeekLow":0.6,"fiftyTwoWeekRange":"0.605 - 3.685","fiftyDayAverage":0.77,"twoHundredDayAverage":0.94,"beta":1.39,"enterpriseValue":34682608,"forwardPE":-3.4,"priceToBook":2.89,"priceToSales":0.8,"enterpriseToRevenue":0.84,"enterpriseToEbitda":-2.66,"pegRatio":0,"ebitda":-13046143,"ebitdaMargin":-31.7,"freeCashflow":-10472450,"operatingCashflow":-14031891,"totalDebt":18961924,"debtToEquity":210.6,"currentRatio":2.73,"returnOnAssets":-22.6,"returnOnEquity":-98.5,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":4,"targetMeanPrice":5.12,"targetHighPrice":9.5,"targetLowPrice":3,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":6.4,"institutionHeldPercent":43,"sharesOutstanding":38638653,"floatShares":27362735,"sharesShort":3840472,"shortRatio":13.17,"shortPercentOfFloat":9.9,"epsTrailing":-0.36,"epsForward":-0.25,"revenuePerShare":1.07,"bookValue":0.3,"officers":[{"age":70,"name":"Mr. Paul R. Gudonis","title":"President, CEO & Chairman"},{"age":64,"name":"Mr. David A. Henry","title":"Chief Financial Officer"},{"age":66,"name":"Dr. Harry  Kovelman M.D.","title":"Chief Medical Officer"},{"age":null,"name":"Mr. Colin  Anderson","title":"Global Director of Operations"},{"age":null,"name":"Ms. Galina  Shtivelman","title":"Senior Director of Human Resources"},{"age":49,"name":"Mr. Micah J. Mitchell","title":"Chief Commercial Officer"},{"age":null,"name":"Ms. Kathy  Sawyers","title":"Sr. Director of Clinical Outcomes"},{"age":null,"name":"Mr. Malcolm G. Bock","title":"Vice President of Engineering & Product Strategy"}],"industry":"Medical Devices","irWebsite":"","website":"https://myomo.com","phone":"617 996 9058"}}